Cargando…

How to select cancer patients for immunotherapy

Detalles Bibliográficos
Autores principales:	Pfeiffer, Per, Qvortrup, Camilla, Hansen, Karin Holmskov
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804597/ https://www.ncbi.nlm.nih.gov/pubmed/33418504 http://dx.doi.org/10.1016/j.ebiom.2020.103184

Ejemplares similares

How to select colorectal cancer patients for personalized therapy
por: Pfeiffer, Per, et al.
Publicado: (2019)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
por: Hansen, Torben Frøstrup, et al.
Publicado: (2021)

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients
por: Pfeiffer, Per, et al.
Publicado: (2009)

Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example
por: Winther, Stine Braendegaard, et al.
Publicado: (2016)

Targetless T cells in cancer immunotherapy
por: thor Straten, Per, et al.
Publicado: (2016)

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis
por: Bjørnhart, Birgitte, et al.
Publicado: (2022)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer
por: Siesing, Christina, et al.
Publicado: (2017)

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I–III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol
por: Justesen, Tobias Freyberg, et al.
Publicado: (2023)

Low-dose irradiation for reversing immunotherapy resistance: how to translate?
por: Ochoa-de-Olza, Maria, et al.
Publicado: (2022)

Congenital hypopituitarism: how to select the patients for genetic analyses
por: Crisafulli, Giuseppe, et al.
Publicado: (2018)

Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9
por: Winther, Stine Braendegaard, et al.
Publicado: (2017)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Defining the critical hurdles in cancer immunotherapy
por: Fox, Bernard A, et al.
Publicado: (2011)

The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients
por: Germani, Marco Maria, et al.
Publicado: (2022)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
por: Eriksen, Martina, et al.
Publicado: (2022)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

Cancer immunotherapy: avoiding the road to perdition
por: Chiriva-Internati, Maurizio, et al.
Publicado: (2004)

Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023)

How targets select activation or repression in response to Wnt
por: Murgan, Sabrina, et al.
Publicado: (2015)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

HSP70-based anti-cancer immunotherapy
por: Guzhova, Irina V., et al.
Publicado: (2016)

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
por: Visconti, Roberta, et al.
Publicado: (2017)

Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer
por: Parikh, Mamta, et al.
Publicado: (2022)

Quantity of Immune Cells Predict Response to Immunotherapy in Cancer
por: Salgado, Roberto, et al.
Publicado: (2021)

Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned
por: Bible, Keith C.
Publicado: (2021)

Immunological barriers to immunotherapy in primary and metastatic breast cancer
por: De Martino, Mara, et al.
Publicado: (2021)

Circulating protein and antibody biomarker for personalized cancer immunotherapy
por: Yuan, Jianda
Publicado: (2016)

TCR diversity – a universal cancer immunotherapy biomarker?
por: McNeel, Douglas G.
Publicado: (2016)

CXCR3: Here to stay to enhance cancer immunotherapy?
por: Rogava, Meri, et al.
Publicado: (2019)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

COVID-19: the use of immunotherapy in metastatic lung cancer
por: Davis, Alexander P, et al.
Publicado: (2020)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Omission of axillary lymph node dissection after neoadjuvant chemotherapy for clinically node‐positive breast cancer: How can we select patients?
por: van Zeeland, Marianne, et al.
Publicado: (2020)

Elderly patients for cancer surgeries: How much to investigate!
por: Garg, Rakesh
Publicado: (2018)

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)

It’s TIME for a biomarker-driven approach to cancer immunotherapy
por: Emens, Leisha A.
Publicado: (2016)

FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
por: Symeonides, Stefan N., et al.
Publicado: (2017)

Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy
por: Raez, Luis E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vpcn5mn15cs4hi8p5hjsve1a1n